Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

Fig. 3

Relationship between PSA concentrations during the therapy and OS or PFS. Time-series changes in log (PSA) for dead patients in OS (a) and censored or surviving patients (b); Time-series changes in log(PSA) for deceased patients in PFS (c) and censored or survived patients (d); changes in a predicted hazard ratio by log(PSA) for OS (e) and PFS (d) with adjusted AGE to 74, the median age of the patients. The PSA concentrations in the dead (a) and progressed patients (c) failed to decrease sufficiently, and the concentrations increased before ten months. The behaviors of PSA concentration curves were different between event-patients and survived or censored patients. Simulated changes in OS risk (e) and PFS risk (f) for a model case (baseline age 74) show that if the log(PSA) > 1 or PSA > 2.7 ng/mL, then the risk can rapidly increase.

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us